Pacira BioSciences (PCRX) Stock: Buy, Sell, or Hold?
PCRX - Pacira BioSciences, Inc. Common Stock
$36.34
0.01 (0.03%)
▲
5d:
+0.03%
30d:
+47.54%
90d:
+40.42%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PCRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PCRX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$41.85
Based on 11.7% avg growth
INTRINSIC VALUE TODAY
$25.99
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $36.34, which is considered extended relative to its 30-day fair value range of $23.50 to $34.49. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.5) compared to its historical average (7.0). At these levels, the market is pricing in 14.6% annual earnings growth.
Technical Outlook: Technically, PCRX is in a uptrend. The price is currently testing key support at $36.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCRX is in a uptrend. The price is currently testing key support at $36.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCRX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$23.50 -
$34.49
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
20.0%
All Signals
- BEARISH: Price extended above range (+5.4% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($33.57)
- BULLISH: Expecting earnings turnaround to 14.6% growth with 6.2% revenue growth
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$23.50 -
$34.49
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$36.30
Resistance Level
$36.67
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.51
Wall Street Target
$33.57
(-7.6%)
Revenue Growth (YoY)
6.2%
Earnings Growth (YoY)
-30.0%
Profit Margin
2.0%
Valuation Premium vs History
+14.6% premium
PE vs Historical
10.5 vs 7.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+14.6%
(market-implied from PE analysis)
1-Year Target
$41.65
(+15%)
2-Year Target
$47.73
(+31%)
3-Year Target
$54.69
(+51%)
3-Yr Target (if PE normalizes)
(PE: 11→7)
PE COMPRESSION
$36.44
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 19.4%)
$117.04
(+222%)
Base:
(SPY PE: 10.5, Growth: 19.4%)
$61.92
(+70%)
Bear:
(PE: 7.0, Growth: 19.4%)
$41.25
(+14%)
📈
Valuation based on Current Earnings
Forward PE: 6.25 | Forward EPS (Implied): $5.81
Bull Case
$43.88
(+21%)
Analyst growth 15.0%, PE expands to 6.6
Base Case
$36.34
(0%)
Market implied 0.0%, PE stable at 6.3
Bear Case
$27.80
(-24%)
Severe decline -15.0%, PE contracts to 5.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 5:43 AM ET
Data refreshes hourly during market hours. Next update: 6:43 AM
Data refreshes hourly during market hours. Next update: 6:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
